ArticleClinica chimica acta; international journal of clinical chemistry2013
Measurement of Hba(1C) in patients with chronic renal failure.
Article in Clinica chimica acta; international journal of clinical chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2022Pooled it
- The predictive value of glycated albumin and hemoglobin A1c for all-cause and cardiovascular mortality in chronic kidney disease patients.Diabetology & metabolic syndrome · 2026Article
- Critical Relationship Between Iron Deficiency Anaemia (IDA) and Glycated Haemoglobin (HbA1c): An Updated Review.Mini reviews in medicinal chemistry · 2026Review
- Glomerular mesangial derived extracellular vesicles deteriorate diabetic kidney disease via miR-3147/PRKAR2B axis.Renal failure · 2025Article
- Stress Hyperglycemia Ratio as a Predictor of In-Hospital Stent Thrombosis in STEMI Patients Undergoing Primary PCI: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Effect of Carbamylation and Anemia on the Association between Glycated Albumin and Kidney Outcomes in Diabetic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Diabetes and Glucose Management in People on Hemodialysis.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Utilising continuous glucose monitoring for glycemic control in diabetic kidney disease.World journal of diabetes · 2024Article
- Article
- Fasting blood glucose and the risk of all-cause mortality in patients with diabetes mellitus undergoing hemodialysis.Kidney research and clinical practice · 2024Article
- Perspective of Continuous Glucose Monitoring-Based Interventions at the Various Stages of Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Framework of Guidelines for Management of CKD in Asia.Kidney international reports · 2024Article
- HbA1c changes in the first year post-kidney transplant and associated risk factors in a Saudi cohort.Therapeutic advances in endocrinology and metabolism · 2024Article
- Protective effect of eriodictyol against hyperglycemia-induced diabetic nephropathy in rats entails antioxidant and anti-inflammatory effects mediated by activating Nrf2.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Mortality prediction in patients with hyperglycaemic crisis using explainable machine learning: a prospective, multicentre study based on tertiary hospitals.Diabetology & metabolic syndrome · 2023Article
- Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review).Experimental and therapeutic medicine · 2022Review
- Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study.Cardiovascular diabetology · 2021Observational
- Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2019Review
- The National Glycohemoglobin Standardization Program: Over 20 Years of Improving Hemoglobin AClinical chemistry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundCarbamylated hemoglobin (carbHb) is reported to interfere with measurement and interpretation of HbA(1c) in diabetic patients with chronic renal failure (CRF). There is also concern that HbA1c may give low results in these patients due to shortened erythrocyte survival.
methodsWe evaluated the effect of carbHb on HbA(1c) measurements and compared HbA(1c) with glycated albumin (GA) in patients with and without renal disease to test if CRF causes clinically significant bias in HbA(1c) results by using 11 assay methods. Subjects included those with and without renal failure and diabetes. Each subject's estimated glomerular filtration rate (eGFR) was used to determine the presence and degree of the renal disease. A multiple regression model was used to determine if the relationship between HbA(1c) results obtained from each test method and the comparative method was significantly (p<0.05) affected by eGFR. These methods were further evaluated for clinical significance by using the difference between the eGRF quartiles of >7% at 6 or 9% HbA(1c). The relationship between HbA(1c) and glycated albumin (GA) in patients with and without renal failure was also compared.
resultsSome methods showed small but statistically significant effects of eGFR; none of these differences were clinically significant. If GA is assumed to better reflect glycemic control, then HbA(1c) was approximately 1.5% HbA(1c) lower in patients with renal failure.
conclusionsAlthough most methods can measure HbA(1c) accurately in patients with renal failure, healthcare providers must interpret these test results cautiously in these patients due to the propensity for shortened erythrocyte survival in renal failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.